首页 / 院系成果 / 成果详情页

Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trial 期刊论文

编号：

A9DC30DADD193F042D837E465C9F5F11
作者：

Chen, SiYuan#^[1,2]Duan, XiaoTong#^[1,2]Li, HuiFeng#^[1,2]Peng, Lan#^[1,2]Wang, ZhiQiang(王志强)#^[3]Xu, GuiQiong^[4];Hua, YiJun(华贻军)^[1,2]Zou, Xiong(邹雄)^[1,2]You, Rui^[1,2]Ouyang, YanFeng^[1,2];Liu, YouPing(刘友平)^[1,2,5]Gu, ChenMei^[1,2];Yang, Qi(杨琦)^[1,2]Jiang, Rou^[1,2];Zhang, MengXia^[1,2];Lin, Mei^[1,2];Xie, YuLong^[1,2];Lin, Chao^[1,2];Ding, Xi^[1,2];Xie, RuoQi^[1,2];Duan, ChongYang(段重阳)^[6]Zhang, WeiJing^[2,7];Huang, PeiYu(黄培钰)^[1,2]Chen, MingYuan(陈明远)*^[1,2,5]
语种：

英文
期刊：

CELL REPORTS MEDICINE ISSN：2666-3791 2023 年 4 卷 11 期 ; NOV 21
收录：
摘要：

Locoregional radiotherapy added to chemotherapy has significantly improved survival in de novo metastatic nasopharyngeal carcinoma (mNPC). However, only 54% of de novo mNPC patients who received sequential chemoradiotherapy have complete or partial response 3 months after radiotherapy. This Simon''s optimal two-stage design phase II study (NCT04398056) investigates whether PD-1 inhibitor could improve tumor control in combination with chemoradiation. The primary endpoint is objective response rate (ORR) at 3 months after radiotherapy. Twenty-two patients with primary mNPC are enrolled. The ORR at 3 months after radiotherapy is 81.8% (22.7% complete response, n = 5; 59.1% partial response, n =13), and the disease control rate is 81.8%. The 3-year progression-free survival (PFS) rate is 44.9% (95% confidence interval 26.4%- 76.3%). Fifteen patients (68.2%) experienced grade 3-4 adverse events. Patients with high baseline plasma Epstein-Barr virus DNA copy number (>10(4) cps/mL) show worse PFS. Addition of toripalimab to sequential chemoradiotherapy suggests promising tumor response in patients with primary mNPC.
推荐引用方式
GB/T 7714：

Chen Si-Yuan,Duan Xiao-Tong,Li Hui-Feng, et al. Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trial [J].CELL REPORTS MEDICINE,2023,4(11).
APA：

Chen Si-Yuan,Duan Xiao-Tong,Li Hui-Feng,Peng Lan,&Chen Ming-Yuan.(2023).Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trial .CELL REPORTS MEDICINE,4(11).
MLA：

Chen Si-Yuan, et al. "Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trial" .CELL REPORTS MEDICINE 4,11(2023).
入库时间：

2023/12/3 13:11:14
更新时间：

2023/12/3 13:11:14
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：26  下载次数：0

分享到：

浏览次数：26

下载次数：0

打印次数：0